PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

1 - 116 . (canceled)

117 . An extended release pharmaceutical tablet comprising:

a stable Freebase form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) that exhibits solubility stability from about 0.2 mg/mL to about 1.2 mg/mL when measured in a FasSIF medium having a pH of 6.5 at 37° C.; and

a hydrophilic polymer;

wherein Compound 1 releases from the extended release pharmaceutical tablet at a steady rate in a use environment.

118 . The extended release pharmaceutical tablet of claim 117 , wherein the stable Freebase form is Freebase Form C or Amorphous Freebase.

119 . The extended release pharmaceutical tablet of claim 118 , wherein the stable Freebase form is Amorphous Freebase.

120 . The extended release pharmaceutical tablet of claim 119 , wherein the hydrophilic polymer is hydroxypropyl methylcellulose.

121 . The extended release pharmaceutical tablet of claim 119 , further comprising an organic acid.

122 . The extended release pharmaceutical tablet of claim 120 , further comprising an organic acid.

123 . The extended release pharmaceutical tablet of claim 121 , wherein the organic acid is selected from the group consisting of tartaric acid, citric acid, succinic acid, fumaric acid, and malic acid.

124 . The extended release pharmaceutical tablet of claim 119 , further comprising a lubricant.

125 . The extended release pharmaceutical tablet of claim 124 , wherein the lubricant is magnesium stearate.

126 . The extended release pharmaceutical tablet of claim 119 , further comprising a glidant.

127 . The extended release pharmaceutical tablet of claim 126 , wherein the glidant is colloidal silica.

128 . The extended release pharmaceutical tablet of claim 119 , further comprising a filler.

129 . The extended release pharmaceutical tablet of claim 128 , wherein the filler is microcrystalline cellulose.

130 . The extended release pharmaceutical tablet of claim 128 , wherein the filler is mannitol.

131 . The extended release pharmaceutical tablet of claim 128 , wherein the filler is mannitol and microcrystalline cellulose.

132 . The extended release pharmaceutical tablet of claim 123 , wherein the organic acid is tartaric acid.

133 . The extended release pharmaceutical tablet of claim 132 , further comprising:

(a) microcrystalline cellulose;

(b) mannitol;

(d) colloidal silica; and

(e) magnesium stearate.

134 . The extended release pharmaceutical tablet of claim 133 , comprising:

(a) about 15 mg, about 30 mg or about 45 mg of Compound 1;

(b) microcrystalline cellulose;

(c) about 21 w/w % mannitol;

(d) about 20 w/w % hydroxypropyl methylcellulose;

(e) about 20 w/w % tartaric acid;

(f) about 0.5 w/w % colloidal silica; and

(g) about 1.5 w/w % magnesium stearate.

135 . The extended release tablet of claim 123 , wherein the organic acid is citric acid.

136 . The extended release tablet of claim 135 , further comprising:

(a) microcrystalline cellulose;

(b) mannitol;

(d) colloidal silica; and

(e) magnesium stearate.

137 . The extended release pharmaceutical tablet of claim 136 , comprising:

(a) about 15 mg, about 30 mg or about 45 mg of Compound 1;

(b) microcrystalline cellulose;

(c) about 21 w/w % mannitol;

(d) about 20 w/w % hydroxypropyl methylcellulose;

(e) about 20 w/w % citric acid;

(f) about 0.5 w/w % colloidal silica; and

(g) about 1.5 w/w % magnesium stearate.

138 . The extended release tablet of claim 123 , wherein the organic acid is succinic acid.

139 . The extended release tablet of claim 138 , further comprising:

(a) microcrystalline cellulose;

(b) mannitol;

(d) colloidal silica; and

(e) magnesium stearate.

140 . The extended release pharmaceutical tablet of claim 139 , comprising:

(a) about 15 mg, about 30 mg or about 45 mg of Compound 1;

(b) microcrystalline cellulose;

(c) about 21 w/w % mannitol;

(d) about 20 w/w % hydroxypropyl methylcellulose;

(e) about 20 w/w % succinic acid;

(f) about 0.5 w/w % colloidal silica; and

(g) about 1.5 w/w % magnesium stearate.

141 . The extended release tablet of claim 123 , wherein the organic acid is fumaric acid.

142 . The extended release tablet of claim 141 , further comprising:

(a) microcrystalline cellulose;

(b) mannitol;

(d) colloidal silica; and

(e) magnesium stearate.

143 . The extended release pharmaceutical tablet of claim 142 , comprising:

(a) about 15 mg, about 30 mg or about 45 mg of Compound 1;

(b) microcrystalline cellulose;

(c) about 21 w/w % mannitol;

(d) about 20 w/w % hydroxypropyl methylcellulose;

(e) about 20 w/w % fumaric acid;

(f) about 0.5 w/w % colloidal silica; and

(g) about 1.5 w/w % magnesium stearate.

144 . The extended release tablet of claim 123 , wherein the organic acid is malic acid.

145 . The extended release tablet of claim 144 , further comprising:

(a) microcrystalline cellulose;

(b) mannitol;

(d) colloidal silica; and

(e) magnesium stearate.

146 . The extended release pharmaceutical tablet of claim 145 , comprising:

(a) about 15 mg, about 30 mg or about 45 mg of Compound 1;

(b) microcrystalline cellulose;

(c) about 21 w/w % mannitol;

(d) about 20 w/w % hydroxypropyl methylcellulose;

(e) about 20 w/w % malic acid;

(f) about 0.5 w/w % colloidal silica; and

(g) about 1.5 w/w % magnesium stearate.